Health Equity & Access Weekly Roundup: April 24, 2026

• The FDA has approved the oral medication ensitrelvir for use as post-exposure prophylaxis (PEP) to prevent the onset of COVID-19 symptoms. • Approval follows phase 3 clinical trial data conducted between February 10 and July 10, 2022, across 92 sites in Japan, Vietnam, and South Korea, demonstrating efficacy against Omicron variants.

• The FDA recently approved the oral antiviral drug ensitrelvir (Xocova) for use as post-exposure prophylaxis (PEP). • The medication is designed to be taken within 72 hours after a person has been exposed to someone with COVID-19 to prevent infection.

• The FDA has approved XOCOVA (ensitrelvir), developed by Shionogi Inc., as a new treatment option for COVID-19. • XOCOVA is distinguished as the first and only oral medication specifically approved to help prevent the onset of COVID-19 following exposure to the virus.

• The FDA has approved ensitrelvir, an oral antiviral medication specifically designed to prevent COVID-19 after a person has been exposed to the virus. • Approval follows the phase III SCORPIO-PEP trial, which demonstrated that the drug reduced the risk of developing COVID-19 by more than half for individuals who were household contacts of an infected person.

• Shionogi has received FDA approval for its protease inhibitor, ensitrelvir, specifically for use in the prevention of COVID-19. • This regulatory win follows a previous failure by the company to demonstrate the drug's effectiveness as a primary treatment for U.S. patients.

• Northern Ireland’s Health Minister has praised a Public Health Agency warning regarding drug use, describing the guidance as "practical." • The statement comes amid legal proceedings where the Minister and his wife, Eleanor Donaldson of Dromore, Co Down, face criminal charges.

• During the week of June 19, 2023, the FDA issued several key approvals, including a $3.2 million gene therapy and the first anti-inflammatory drug designed for cardiovascular disease. • Other approved treatments include a subcutaneous version of Vyvgart for myasthenia gravis and the expansion of Jardiance and Synjardy for pediatric patients with type 2 diabetes.

• The Centers for Disease Control and Prevention (CDC) is seeking public and agency comments on a proposed continuing information collection project. • The project focuses on the "Use of the Cyclosporiasis National Hypothesis Generating Questionnaire (CNHGQ)" during investigations of foodborne disease clusters and outbreaks.

• Researchers are analyzing the current debate regarding the construction of layperson summaries for clinical trial results within the European Union. • The authors propose a "reader-centered" approach that prioritizes the most critical information for patients, specifically the efficacy and safety of the drug.

• Author of the new book "Decolonising Disease: Pandemics, Public Health and Pathogenic Novels" explores the intersection of colonialism, imperialism, and epidemic disease. • The work draws critical parallels between the COVID-19 pandemic and historical Ebola outbreaks, specifically those in Congo/Zaire and Sudan in 1976 and West Africa from 2014–16.

• Following the resignation of Commissioner Marty Makary, the FDA is seeking a new leader to oversee the agency's commitment to accelerating treatment access for rare disease patients. • The urgency is highlighted by UX111 gene therapy, which clinical trials show can reduce toxin buildup for over eight years and slow cognitive decline if administered early.